期刊文献+

氟伐他汀对慢性心力衰竭患者心功能、炎症因子及预后的影响 被引量:1

Clinical Observation on Fluvastatin for Improving Prognosis and Changes Of Inflammatory Factors In Patients with Chronic Heart Failure
暂未订购
导出
摘要 【目的】观察氟伐他汀对慢性心力衰竭患者预后的影响及治疗后炎症因子的改变。【方法】慢性心力衰竭住院患者89例,随机分成氟伐他汀观察组(45例),对照组(44例)。两组患者均按常规治疗,观察组加用氟伐他汀40mg,每晚1次,治疗12周后复查高敏C反应蛋白(HS—CRP)、肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)及测量左室射血分数(LVEF),评估心功能。【结果】治疗12周后,观察组较治疗前及对照组Hs-CRP、TNF-α、IL-6均有明显的降低(P〈0.05),LVEF则有明显提高(P〈0.05)。随访2年,观察组病死率明显降低(P〈0.01)。【结论】氟伐他汀治疗慢性心力衰竭能够改善患者的预后及降低炎症因子。 [Objective] To observe the effects of fluvastatin on the prognosis of patients with chronic heart failure and to investigate the changes of serum levels of inflammatory factors after treatment. [Methods] A total of 89 patients with chronic heart failure were randomly divided into fluvastatin observation group ( n = 45) and the control group( n =44). All patientsreceived conventional treatment, and the observation group received conventional treat- ment plus fluvastatin 40mg/d (once a night). After treatment of 12 weeks, high sensitivity C-reactive protein(HsCRP), tumor necrosis factor-α(TNF-a), interleukin-6(IL-6) and left ventricular ejection fraction (LVEF) of cardiac were examined, and the cardiac function was also evaluated. [Results] After treatment of 12 weeks, serum Hs-CRP, TNF-α and IL-6 in the observation group decreased at varying degrees in comparison with control group( P 〈0.05). Furthermore, LVEF significantly improved ( P 〈0.05). With 2-year follow-up, the case-fatality rate in the observation group decreased rapidly ( P 〈0. 01). [Conclusion] Fluvastatin can improve the prognosis and reduce the levels of serum inflammatory factors of patients with chronic heart failure.
出处 《医学临床研究》 CAS 2009年第11期2093-2095,共3页 Journal of Clinical Research
关键词 心力衰竭 充血性/药物疗法 预后 普伐他丁/治疗应用 heart failure,congestive/DT prognosis prevastatin/TU
  • 相关文献

参考文献9

  • 1Hidekatsu F,David CS,Stefen B, et al . Statin therapy may be associated with lower mortality in patients with diastolic heart failure., a preliminary report[J]. Circulation , 2005, 111 (2) : 357-363.
  • 2Hernandez-Presa MA, Martin-Ventura JL, Ortego M, et al. Atorvastatin reduces the expression of cycloxgenase-2 in a rabbit model of atherosclemsis and in cultured vascular smooth muscle cells[J]. Athemsclerosis , 2002,160 (1) : 49-58.
  • 3Bauersachs J. Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme a reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction[J]. Circulation ,2001,104(2), 982-985.
  • 4Sola S. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure[J]. J Am Coll Cardiol ,2006,47(1), 332-337.
  • 5Kjekshus J. Rosuvastatin in older patients with systolic heart failure[J]. N Engl J Med ,2007,357(3), 2248-2261.
  • 6Node K,Fujita M,Kitakaze M, et al . Short term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy [J]. Circulation , 2003, 108 (7) :839-843.
  • 7SOLA S, MIR M Q, LERAKIS S, et al . Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonisehemie heart failure[J]. J Am Coll Cardiol , 2006,47(2) :332-337.
  • 8Hans C, Ablij, Arend E. Meinders C-reactive protein: history and revival[J]. European Journal of internal Medicine ,200, 13 : 412-422.
  • 9Keith M,Geranmayegan A, Sole MJ, et al . Increased oxidative stress in patients with congestive heart failure[J]. J Am Coll Cardiol ,1998,31(6) :1352-1356.

同被引文献7

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部